Pixium Vision SA (ALPIX.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALPIX - FR001400JX97 - Common Stock
ALPIX.PA Key Statistics, Chart & Performance
The current stock price of ALPIX.PA is 0.3764 EUR. In the past month the price increased by 77.55%. In the past year, price increased by 453.53%.
ALPIX.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.17 | 105.46B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 18.79 | 50.67B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 15.7 | 22.38B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 15.64 | 22.29B | ||
| BIM.PA | BIOMERIEUX | 28.58 | 13.06B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 138.83 | 4.18B | ||
| DIA.MI | DIASORIN SPA | 20.73 | 3.84B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 24.84 | 3.58B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 10.73 | 1.30B | ||
| ELN.MI | EL.EN. SPA | 21.83 | 1.12B | ||
| DRW8.DE | DRAEGERWERK AG | 8.74 | 1.06B | ||
| EUZ.DE | ECKERT & ZIEGLER SE | 23.48 | 969.32M |
Related stock screener links
About ALPIX.PA
Company Profile
Pixium Vision SA is a FR-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Paris, Ile-De-France and currently employs 42 full-time employees. The company went IPO on 2014-06-19. Pixium Vision SA is a France-based company that specializes in sensory neuromodulation. The firm is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The firm develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The firm has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).
Company Info
Pixium Vision SA
74 rue du Faubourg Saint-Antoine
Paris ILE-DE-FRANCE FR
Employees: 42
Phone: 33176214768
Pixium Vision SA / ALPIX.PA FAQ
What does ALPIX do?
Pixium Vision SA is a FR-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Paris, Ile-De-France and currently employs 42 full-time employees. The company went IPO on 2014-06-19. Pixium Vision SA is a France-based company that specializes in sensory neuromodulation. The firm is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The firm develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The firm has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).
What is the stock price of Pixium Vision SA today?
The current stock price of ALPIX.PA is 0.3764 EUR. The price decreased by -10.17% in the last trading session.
What is the dividend status of Pixium Vision SA?
ALPIX.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALPIX stock?
ALPIX.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is ALPIX.PA stock listed?
ALPIX.PA stock is listed on the Euronext Paris exchange.
How is the valuation of Pixium Vision SA (ALPIX.PA) based on its PE ratio?
Pixium Vision SA (ALPIX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.99).
ALPIX.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ALPIX.PA. When comparing the yearly performance of all stocks, ALPIX.PA is one of the better performing stocks in the market, outperforming 99.88% of all stocks.
ALPIX.PA Financial Highlights
Over the last trailing twelve months ALPIX.PA reported a non-GAAP Earnings per Share(EPS) of -7.99. The EPS increased by 29.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -154.03% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALPIX.PA Forecast & Estimates
9 analysts have analysed ALPIX.PA and the average price target is 45.9 EUR. This implies a price increase of 12094.47% is expected in the next year compared to the current price of 0.3764.
For the next year, analysts expect an EPS growth of 55% and a revenue growth -5.17% for ALPIX.PA